All News

Is the UK really neglecting a clean source of energy? Before throwing money into fuel cells, potential investors might like to ask where the energy comes from.

The Department of Trade and Industry has set out a new set of priorities for its investment in R&D. The usual mixed bag, with a nod towards climate change.

Blue biotech is getting into its stride, as the tools of genomics and high throughput screening are applied to unlock the chemical diversity of the oceans.

How will Imperial College London's newly floated tech-transfer affiliate invest its stock-market millions? After raising the money, now comes the fun part: spending it.

It is a hard life being an electronics business, they just keep changing the science under you. This time around we have a combination of electronics and spin – and that has nothing to do with PR.

An interesting set of deals bring together major companies and the Engineering and Physical Sciences Research Council in a new model for academic/industry collaboration.

Merlin Biosciences has been under the cloud of an investigation by the UK's Serious Fraud Office. Now founder Chris Evans says the firm is planning new investments.

The UK government said it will contribute £16 million to a £32 million programme aimed at ensuring the safe operation of unmanned aviation vehicles (UAV) in civil airspace.

Biotech start-ups in France and elsewhere in Europe make a unique and important contribution to healthcare. They merit special treatment to help them grow.

The GREAT Consortium has been set up to design a mass market receiver for Galileo, Europe's new global satellite navigation system that is due to come into operation in 2012.

The European Commission adopted new rules for investing public money in small private companies that it says will make it easier for start-ups to raise risk capital.

PharmaLinks, a business dedicated to commercialising pharmaceutical research, is looking for a development partner for an immunosuppressive cytokine with therapeutic potential in inflammatory diseases including rheumatoid arthritis, asthma, COPD and arteriosclerosis.

Yochai Benkler and Lawrence Lessig are two well-known law professors affiliated with very prestigious US universities, Yale and Stanford, respectively. They are specialised in intellectual property like policemen are specialised in crime: it is their bailiwick but they do not particularly like it.

The American Bar Association makes available its take on the USA's "federal environmental statutes" and their implications for nanotechnology.

The Food Standards Agency in the UK has published its Science Strategy 2005-10